Avista Healthcare
Raleigh, N.C., August 11, 2015 (GLOBE NEWSWIRE) — INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to Phase IV contract research organization, announced the pricing of its secondary offering of 8,000,000 shares of its Class A common stock by certain of its existing stockholders, including affiliates of Avista Capital Partners, L.P.; affiliates of […]
Trimb Healthcare AB (“Trimb”) and Avista Capital Partners (“Avista”), a leading private equity firm, today announced that Avista is partnering with the company’s founders and management, as well as its founding investor, HealthCap, to build Trimb into a leading OTC and consumer healthcare company. Avista has made a significant capital commitment to accelerate Trimb’s growth […]
N. Billerica, MA – June 24, 2015 – Lantheus Holdings, Inc. (“Lantheus Holdings” or the “Company”), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents and products, announced today the pricing of its initial public offering of 10,833,334 shares of its common […]
Yardley, PA, June 24, 2015 – (Business Wire) OptiNose today announced positive results from its first phase III controlled clinical trial, NAVIGATE II, evaluating the safety and efficacy of OPN-375, an investigational treatment for nasal polyps, a type of Chronic Nasal Inflammatory Disease (CNID), and the associated chronic symptoms. OPN-375 demonstrated statistically significant effects on […]
Raleigh, N.C., May 7, 2015 – INC Research Holdings, Inc. (Nasdaq: INCR), a leading global Phase I to Phase IV contract research organization, announced the pricing of its secondary offering of 7,000,000 shares of its Class A common stock at a price of $31.00 per share. All of the shares are being sold by existing […]
New York, NY, April 7, 2015 – Avista Capital Partners, a leading private equity firm, today announced that Robert P. O’Neil has joined the firm as an Operating Executive focused on consumer-related healthcare investments. Mr. O’Neil has more than 35 years of operational and strategic business leadership experience and a proven track record of building […]
Raleigh, N.C., Nov. 6, 2014 – INC Research Holdings, Inc. (INC Research), a leading, global Phase I to IV contract research organization, today announced the pricing of its initial public offering of 8,108,108 shares of its Class A common stock at a price to the public of $18.50 per share. The shares of INC Research’s […]
Radnor, PA, October 1, 2014 – VWR Corporation (NASDAQ: VWR) announced today that it has priced an underwritten initial public offering of 25,532,000 shares of its common stock at a price to the public of $21.00 per share. The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol […]
AVP-825, Using OptiNose’s Patented Bi-Directional™ Breath Powered™ Technology for Intranasal Delivery of Low-dose Sumatriptan, Demonstrates Greater Reduction in Migraine Pain Compared to the Highest Dose of Oral Sumatriptan Yardley, PA, June 10, 2014 – /PRNewswire/ — OptiNose today announced that the COMPASS trial, a head-to-head comparison of the investigational treatment AVP-825 to sumatriptan tablets, currently […]
Avista Capital Partners-Backed Company to Continue Add-On Acquisition Strategy Sayreville, NJ, March 24, 2014 – Vertical Pharmaceuticals, LLC, a wholly owned subsidiary of Vertical /Trigen Holdings, LLC (“Vertical / Trigen”), today announced that it has acquired the rights to three branded women’s health products from Upsher-Smith Laboratories, Inc. The terms of the transaction were not […]
Acquisition provides customers improved access to Middle East and North Africa region as well as Southern Europe Raleigh, N.C., March 6, 2014 – INC Research LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced it has acquired MEK Consulting, a leading clinical monitoring-focused CRO based […]
AVP-825 uses novel Breath Powered™ drug delivery to treat migraine Yardley, PA, January 30, 2014 – A New Drug Application (NDA) was submitted on Monday January 27, 2014 to the U.S. Food and Drug Administration for AVP-825, a product using OptiNose’s innovative closed-palate Breath Powered intranasal delivery system to deliver low-dose sumatriptan powder for the […]